Precision BioSciences, Inc. (DTIL)
NASDAQ: DTIL · Real-Time Price · USD
7.18
+0.02 (0.28%)
At close: Nov 20, 2024, 4:00 PM
7.00
-0.18 (-2.51%)
After-hours: Nov 20, 2024, 5:31 PM EST
Precision BioSciences Revenue
Precision BioSciences had revenue of $576.00K in the quarter ending September 30, 2024, a decrease of -95.61%. This brings the company's revenue in the last twelve months to $75.10M, up 43.62% year-over-year. In the year 2023, Precision BioSciences had annual revenue of $48.73M with 94.15% growth.
Revenue (ttm)
$75.10M
Revenue Growth
+43.62%
P/S Ratio
0.56
Revenue / Employee
$688,954
Employees
109
Market Cap
51.94M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
111, Inc. | 2.03B |
Apyx Medical | 48.54M |
Cytosorbents | 37.74M |
Enzo Biochem | 31.91M |
Kronos Bio | 9.86M |
Milestone Scientific | 8.88M |
DTIL News
- 6 days ago - Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B - Business Wire
- 17 days ago - Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update - Business Wire
- 23 days ago - Precision BioSciences to Report Third Quarter Results on November 4, 2024 - Business Wire
- 24 days ago - Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024 - Business Wire
- 27 days ago - Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress - Business Wire
- 27 days ago - Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B - Business Wire
- 4 weeks ago - Precision BioSciences to Participate in Upcoming Longwood Boston CEO and Guggenheim Healthcare Conferences - Business Wire
- 5 weeks ago - Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress - Business Wire